EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Relative Efficacy, Effectiveness and Safety of Newer and/or Enhanced Seasonal Influenza Vaccines for the Prevention of Laboratory‐Confirmed Influenza in Individuals Aged 18 years and Over: Update of a Systematic Review

Mona Askar, Karam Adel Ali, Madeleine Batke, Timo Brugger, Annika Falman iD, Anna Hayman Robertson, Jaime Jesús Pérez, Kari Johansen, Jorgen de Jonge iD, Tyra Grove Krause, Wiebe Külper-Schiek, Joerg J Meerpohl und 14 weitere

Reviews in Medical Virology · 2025-03 · 35 (2)

DOI: 10.1002/rmv.70020 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Reviews in Medical Virology, online erschienen am 24.02.2025. Verfasst von Mona Askar und 25 weiteren Autor:innen. Beteiligte Einrichtung: Immunisation Unit, Robert Koch Institute, Berlin, Germany. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Vaccine Efficacy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Health and Digital Executive Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We performed an update (last search: 24 July 2023) of a systematic review on relative efficacy/effectiveness (rVE) and safety of newer/enhanced seasonal influenza vaccines in comparison with standard influenza vaccine or in head‐to‐head comparison. Eligible studies investigated adults aged ≥ 18 years, analysed the MF59‐adjuvanted or high‐dose or cell‐based or recombinant or mRNA‐based influenza vaccine and reported rVE or safety in randomised controlled trials (RCT) or non‐randomised studies of interventions (NRSI). Of 1561 new entries identified, 17 studies were included. Together with 42 studies identified in the previous primary review they added up to 59 studies, all comparing newer/enhanced with standard seasonal influenza vaccines. Relative VE against laboratory‐confirmed influenza was −30% (95%CI: −146% to 31%) to 88% (51%–100%; 7 NRSI) for the MF59‐adjuvanted vaccine (low certainty of evidence, CoE); 24.2% (9.7%–36.5%; 1 RCT) and −9% (−158% to 54%) to 19% (−27% to 48%; 1 NRSI) for the high‐dose vaccine (moderate CoE); −5.8% (−36.1% to 17.7%) to 21.4% (−7.3% to 42.4%; 2 NRSI) for the cell‐based vaccine (low CoE); 30% (10%–47%; 1 RCT) and 3% (−31% to 28%) to 19% (−27% to 48%; 1 NRSI) for the recombinant vaccine (moderate CoE), respectively. Relative VE against laboratory‐confirmed influenza‐related hospitalisation was 59.2% (14.6%–80.5%; 1 NRSI) for the MF59‐adjuvanted (moderate CoE); 27% (−1 to 48%; 1 NRSI) for the high‐dose (low CoE); 8.5% (−75.9% to 52.3%; 1 NRSI) for the cell‐based (low CoE); −7.3% (−52.1% to 24.4%) to 16.3% (−8.7% to 35.5%; 1 RCT) for the recombinant vaccine. No increased risk of serious adverse events was detected for any vaccine (12 RCT, 7 NRSI; low CoE). While all have a favourable safety profile, evidence on rVE of newer/enhanced vaccines is still limited, warranting further studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanVaccine EfficacyHumansAdjuvants, ImmunologicAdultSqualeneAdolescentPolysorbatesRandomized Controlled Trials as TopicSeasonsYoung Adult

Substanzen

Influenza VaccinesAdjuvants, ImmunologicMF59 oil emulsionSqualenePolysorbates

Autor:innen und Institutionen

  • Immunisation Unit, Robert Koch Institute, Berlin, Germany.
  • European Centre for Disease Prevention and Control, Solna, Sweden.
  • Faculty of Medicine, Institute for Evidence in Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
  • Cochrane Germany, Cochrane Germany Foundation, Freiburg, Germany.
  • Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
  • General Directorate of Public Health and Addictions, IMIB-Arrixaca, Murcia University, Region of Murcia, Spain.

ORCID-Profile: Annika Falman, Jorgen de Jonge, Thomas Harder

Förderung

  • European Health and Digital Executive Agency

Zitieren

APA

Askar, M., Ali, K. A., Batke, M., Brugger, T., Falman, A., Robertson, A. H., Pérez, J. J., Johansen, K., de Jonge, J., Krause, T. G., Külper-Schiek, W., Meerpohl, J. J., Melidou, A., Nohynek, H., Olmedo, C., Olsson, K., Pavlopoulou, I., Piechotta, V., Rubin, J., …, & Harder, T. (2025). Relative Efficacy, Effectiveness and Safety of Newer and/or Enhanced Seasonal Influenza Vaccines for the Prevention of Laboratory‐Confirmed Influenza in Individuals Aged 18 years and Over: Update of a Systematic Review. Reviews in Medical Virology, 35(2). https://doi.org/10.1002/rmv.70020

Vancouver

Askar M, Ali KA, Batke M, Brugger T, Falman A, Robertson AH, et al. Relative Efficacy, Effectiveness and Safety of Newer and/or Enhanced Seasonal Influenza Vaccines for the Prevention of Laboratory‐Confirmed Influenza in Individuals Aged 18 years and Over: Update of a Systematic Review. Reviews in Medical Virology. 2025;35(2). doi:10.1002/rmv.70020

BibTeX
@article{Askar2025,
  author = {Askar, Mona and Ali, Karam Adel and Batke, Madeleine and Brugger, Timo and Falman, Annika and Robertson, Anna Hayman and Pérez, Jaime Jesús and Johansen, Kari and de Jonge, Jorgen and Krause, Tyra Grove and Külper-Schiek, Wiebe and Meerpohl, Joerg J and Melidou, Angeliki and Nohynek, Hanna and Olmedo, Carmen and Olsson, Kate and Pavlopoulou, Ioanna and Piechotta, Vanessa and Rubin, Johanna and Schlaberg, Johanna and Schmucker, Christine and Siemens, Waldemar and Stratil, Jan and Učakar, Veronika and Wichmann, Ole and Harder, Thomas},
  title = {Relative Efficacy, Effectiveness and Safety of Newer and/or Enhanced Seasonal Influenza Vaccines for the Prevention of Laboratory‐Confirmed Influenza in Individuals Aged 18 years and Over: Update of a Systematic Review},
  journal = {Reviews in Medical Virology},
  year = {2025},
  volume = {35},
  number = {2},
  doi = {10.1002/rmv.70020}
}
Kostenlos starten →